drugset / Trial / NCT07672223
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).
Timeline
- Start
- 2026-06-25
- Primary completion
- 2029-09-30
- Completion
- 2031-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Durvalumab | Monoclonal antibody | — | — |
| Subject | Enlonstobart | Monoclonal antibody | — | — |
| Comparator | Nivolumab | Monoclonal antibody | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | SYS6010 | Monoclonal antibody | — | — |
| Comparator | Tislelizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Toripalimab | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Pemetrexed | Small molecule | — | — |